Literature DB >> 31069157

Toll-like receptor 3 acts as a suppressor gene in breast cancer initiation and progression: a two-stage association study and functional investigation.

Lei Fan1, Peng Zhou2, Qi Hong1, Ao-Xiang Chen1, Guang-Yu Liu1, Ke-Da Yu1, Zhi-Ming Shao1.   

Abstract

Toll-like receptor 3 (TLR3) is a receptor recognizing double-stranded RNA (dsRNA) from viruses as well as from lytic mammalian cells. In the present study, we performed a two-stage association study (n = 3,551) and found that the minor alleles of two SNPs (the T-allele of rs5743312 and the T-allele of rs3775296) conferred increased risks of breast cancer incidence. The adjusted odds ratios (ORs) were 2.281 (P = 7.01 × 10-5) and 2.086 (P = 8.69 × 10-5), respectively. Specifically, the susceptibility variants within TLR3 were significantly associated with larger tumor size (adjusted P-values: 0.004 for rs5743312 and 0.004 for rs3775296). Furthermore, we investigated the biological function of the TLR3 protein in breast cancer cell lines. Notably, the stable expression of TLR3 directly inhibited cell proliferation both in vitro and in vivo. We also verified that TLR3 conferred less invasive phenotypes on breast cancer cells by regulating the mRNA expression of a panel of genes. TLR3-mediated inhibition of proliferation was caused by downregulation of the EGFR/PI3K/AKT pathway. In summary, our findings strongly suggest that common genetic changes in the TLR3 gene may influence breast cancer susceptibility and development, and TLR3 plays a negative regulatory role in the initiation and progression of human breast cancer cells, at least in part by downregulating the EGFR/PI3K/AKT pathway.

Entities:  

Keywords:  Toll-like receptor 3; breast cancer; double-stranded RNA

Year:  2019        PMID: 31069157      PMCID: PMC6492959          DOI: 10.1080/2162402X.2019.1593801

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  53 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery.

Authors:  Peter A Bell; Surendra Chaturvedi; Craig A Gelfand; Ching Yu Huang; Michael Kochersperger; Rafael Kopla; Frank Modica; Mark Pohl; Shobha Varde; Renbin Zhao; Xiaojian Zhao; Michael T Boyce-Jacino; Azzam Yassen
Journal:  Biotechniques       Date:  2002-06       Impact factor: 1.993

3.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.

Authors:  Kirk E Lohmueller; Celeste L Pearce; Malcolm Pike; Eric S Lander; Joel N Hirschhorn
Journal:  Nat Genet       Date:  2003-01-13       Impact factor: 38.330

Review 4.  Benign breast disorders.

Authors:  Richard J Santen; Robert Mansel
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

5.  The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I.

Authors:  Simon Rothenfusser; Nadege Goutagny; Gary DiPerna; Mei Gong; Brian G Monks; Annett Schoenemeyer; Masahiro Yamamoto; Shizuo Akira; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

6.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

Review 7.  Breast cancer susceptibility-A new look at an old model.

Authors:  Julian Peto
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

8.  mRNA is an endogenous ligand for Toll-like receptor 3.

Authors:  Katalin Karikó; Houping Ni; John Capodici; Marc Lamphier; Drew Weissman
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

9.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

Review 10.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

View more
  6 in total

1.  Multi-omics analysis reveals the panoramic picture of necroptosis-related regulators in pan-cancer.

Authors:  Guanghao Li; Xiaoxuan Wang; Yongheng Liu; Huikai Li; Han Mu; Yanting Zhang; Qiang Li
Journal:  Aging (Albany NY)       Date:  2022-06-21       Impact factor: 5.955

2.  Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma.

Authors:  Ang Li; Hongjiao Wu; Qinqin Tian; Yi Zhang; Zhi Zhang; Xuemei Zhang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

3.  Association of TLR3 single nucleotide polymorphisms with susceptibility to HTLV-1 infection in Iranian asymptomatic blood donors.

Authors:  Hossein Mehrabi Habibabadi; Masoud Parsania; Ali Akbar Pourfathollah; Setareh Haghighat; Zohreh Sharifi
Journal:  Rev Soc Bras Med Trop       Date:  2020-06-22       Impact factor: 1.581

4.  Bioinformatics analysis of C3 and CXCR4 demonstrates their potential as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC).

Authors:  Jing Quan; Yuchen Bai; Yunbei Yang; Er Lei Han; Hong Bai; Qi Zhang; Dahong Zhang
Journal:  BMC Cancer       Date:  2021-07-15       Impact factor: 4.430

5.  Toll-like receptor 3 -926T>A increased the risk of breast cancer through decreased transcriptional activity.

Authors:  Lei Fan; Peng Zhou; Ao-Xiang Chen; Guang-Yu Liu; Ke-Da Yu; Zhi-Ming Shao
Journal:  Oncoimmunology       Date:  2019-10-15       Impact factor: 8.110

Review 6.  The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines.

Authors:  Benjamin Gordon; Vijayakrishna K Gadi
Journal:  Vaccines (Basel)       Date:  2020-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.